Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
PRNewswire - November 19, 2004
The Auxilium study explored the effect of Testim(R) 5g therapy in 48 hypogonadal, HIV positive men who reported that they did not have adequate symptom relief with AndroGel 5g. Auxilium reported that, compared to AndroGel treated men, at the 4-week follow-up, men treated with Testim(R) reported a statistically and clinically significant improvement in their sex drive, erectile function, and satisfaction with sex life as well as being more satisfied with androgen therapy. Additionally, the investigators rated their overall satisfaction with androgen therapy significantly higher in the Testim(R) treated group as compared to the AndroGel treated group. Auxilium reported that these improvements in sexual function resulted in significantly fewer Testim(R) treated men requiring titration to a higher dose compared to men treated with AndroGel (30% vs 74%, respectively).
"We are pleased and encouraged by Auxilium's study data, which we believe further validate the effectiveness of Bentley's proprietary drug delivery technology," stated James R. Murphy, Chairman and CEO of Bentley. "We look forward to bringing CPE-215's benefits to bear for the effective, convenient delivery of a wide range of drugs."
Hypogonadism among HIV Positive Men
Hypogonadal men exhibit lower than normal levels of testosterone, resulting in a variety of symptoms including low energy levels, loss of sex drive, decreased sexual performance, loss of muscle mass, reduced bone density, increased body fat, and mild depression. Symptoms of fatigue, decreased muscle mass, reduced libido, reduced sexual functioning, and depressed mood are often associated with low testosterone (T) levels in hypogonadal, HIV positive men.
About Testim(R) 1%
Testim(R) is a marketed, proprietary, once-a-day, topical 1% testosterone gel that treats hypogonadism by raising testosterone blood levels back to normal. Testim(R) is packaged in convenient, easy-to-open, single-use tubes. Patients apply Testim(R) once a day to the upper arms and shoulders and its active ingredient, testosterone, is absorbed through the skin and into the bloodstream.
Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and pharmaceutical products. Bentley's proprietary drug technologies enhance or facilitate the absorption of pharmaceutical compounds across various membranes. Bentley also manufactures and markets a growing portfolio of generic and branded pharmaceuticals in Europe for the treatment of cardiovascular, gastrointestinal, infectious and neurological diseases through its subsidiaries, Laboratorios Belmac, Laboratorios Davur and Laboratorios Rimafar; and manufactures and sells active pharmaceutical ingredients through its subsidiary, Bentley API.
Copies of Bentley Pharmaceuticals' press releases and other information may be obtained through Bentley's web site at http://www.bentleypharm.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward looking statements, including without limitation, statements regarding the interpretation of the clinical results, and the prospects for Testim(R) and for our proprietary drug delivery technologies. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to risks associated with the timing and results of clinical trials, efficacy and safety of our products, the timing and nature of regulatory approvals, development and commercialization of our products, competition from other manufacturers of proprietary pharmaceuticals, intellectual property litigation, and other uncertainties detailed in Bentley's most recent Annual Report on Form 10-K and its other subsequent periodic reports filed with the Securities and Exchange Commission. Bentley cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Bentley undertakes no obligation to update or revise the statements, except as may be required by law.
SOURCE Bentley Pharmaceuticals, Inc.
Web Site: http://www.bentleypharm.com
041119
PR041134
Copyright © 2004 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .